Tracking pertussis and evaluating control measures through enhanced pertussis surveillance, emerging infections program, United States

Emerging Infectious Diseases

Volumn 21, Issue 9, 2015, Pages 1568-1573

  Skoff, Tami H ^a   Baumbach, Joan ^b   Cieslak, Paul R ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW MEXICO DEPARTMENT OF HEALTH   (United States)

^c OREGON HEALTH AUTHORITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA TOXOID; TETANUS TOXOID; PERTUSSIS VACCINE;

AGE DISTRIBUTION; ANTIMICROBIAL THERAPY; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL EVALUATION; COUGHING; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EMERGING INFECTIONS PROGRAM; ETHNICITY; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTERVIEW; MOLECULAR EPIDEMIOLOGY; MORBIDITY; PERTUSSIS; PUBLIC HEALTH SERVICE; REAL TIME POLYMERASE CHAIN REACTION; UNITED STATES; VACCINATION; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; HEALTH SURVEY; IMMUNOLOGY; OUTCOME ASSESSMENT; STANDARDS; WHOOPING COUGH;

BORDETELLA PERTUSSIS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PERTUSSIS VACCINE; PUBLIC HEALTH SURVEILLANCE; UNITED STATES; VACCINATION; WHOOPING COUGH;

EID: 84939550565     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2109.150023     Document Type: Article

References (19)

1. Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis. 2014;209:978-81. http://dx.doi.org/10.1093/infdis/jiu001
2. Centers for Disease Control and Prevention. Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61:517-22.
3. Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21:119-25. http://dx.doi.org/10.1128/CVI.00717-13
4. Adams DA, Jajosky R, Ajani U, Kriseman J, Sharp P, Onwen D, et al. Summary of notifiable diseases-United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;61:1-121.
5. Pinner RW, Rebmann C, Schuchat A, Hughes J. Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis. 2003;9:781-7.
6. Council of State and Territorial Epidemiologists. Revision of the pertussis surveillance case definition to more accurately capture the burden of disease among infants <1 year of age, 2013 [cited 2014 Oct 30]. http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/13-ID-15.pdf
7. Kamiya H, Faulkner AE, Miller L, Kudish K, Kenyon C, Selvage WD, et al. Enhanced pertussis surveillance: a model for obtaining high-quality surveillance data. Presented at: Council of State and Territorial Epidemiologists (CSTE) Annual Conference; 2014 Jun 22-26; Nashville, Tennessee, USA.
8. Levri KM, Reynolds L, Liko J, Robinson B, Cieslak P. Hispanic infants age <6 months and factors associated with an increased risk for pertussis Metropolitan Portland, Oregon, 2010-2012. Presented at: Council of State and Territorial Epidemiologists (CSTE) Conference Annual Conference; 2013 Jun 9-13; Pasadena, California, USA.
9. Barlow RS, Reynolds LE, Cieslak PR, Sullivan AD. Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 2010-2012. Clin Infect Dis. 2014;58:1523-9. http://dx.doi.org/10.1093/cid/ciu156
10. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62:131-5.
11. Skoff TH, Kenyon C, Cocoros NM, Barron G, Barnes M, Kudish K, et al. Pertussis in infants: source of infection following Tdap introduction. Presented at: Council of State and Territorial Epidemiologists Conference (CSTE) Annual Conference; 2012 Jun 3-7; Omaha, Nebraska, USA.
12. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23:985-9. http://dx.doi.org/ 10.1097/01.inf.0000145263.37198.2b
13. Wendelboe AM, Njamkepo E, Bourillon A, Floret D, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26: 293-9. http://dx.doi.org/ 10.1097/01.inf.0000258699.64164.6d
14. Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, Qin X, et al. Pertactin-negative B. pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60:223-7. http://dx.doi.org/10.1093/cid/ciu788
15. Englund JA, Anderson EL, Reed GF, Decker MD, Edwards KM, Pichichero ME, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96:580-4.
16. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005;24:S62-5. http://dx.doi.org/10.1097/01.inf.0000160915.93979.8f
17. Libster R, Edwards K. How can we best prevent pertussis in infants? Clin Infect Dis. 2012;54:85-7. http://dx.doi.org/10.1093/cid/cir780
18. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014;384:1521-8. http://dx.doi.org/10.1016/S0140-6736(14)60686-3
19. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis. 2015;60:333-7. http://dx.doi.org/10.1093/cid/ciu821